Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...
A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...
Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...
Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...
Incyte is preparing to take an oral JAK inhibitor ... for patients whose lesions cover 10% of the body or less. New drug candidate povorcitinib is a selective JAK1 inhibitor, given as a once ...
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Incyte shares declined after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis suppurativa (HS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback